PMID- 31333107
OWN - NLM
STAT- MEDLINE
DCOM- 20200415
LR  - 20200415
IS  - 1873-4286 (Electronic)
IS  - 1381-6128 (Linking)
VI  - 25
IP  - 22
DP  - 2019
TI  - Diet and Nutritional Interventions with the Special Role of Myo-Inositol in 
      Gestational Diabetes Mellitus Management. An Evidence-Based Critical Appraisal.
PG  - 2467-2473
LID - 10.2174/1381612825666190722155512 [doi]
AB  - BACKGROUND: Gestational Diabetes Mellitus (GDM), defined as glucose intolerance 
      with onset or first recognition during pregnancy, represents one of the most 
      common maternal-fetal complications during pregnancy and it is associated with 
      poor perinatal outcomes. To date, GDM is a rising condition over the last decades 
      coinciding with the ongoing epidemic of obesity and Type 2 Diabetes Mellitus 
      (T2DM). OBJECTIVE: The aim of this review is to discuss the role of diet and 
      nutritional interventions in preventing GDM with the explanation of the special 
      role of myo-inositol (MI) in this matter. METHODS: We performed an overview of 
      the most recent literature data on the subject with particular attention to the 
      effectiveness of diet and nutritional interventions in the prevention of GDM with 
      the special role of MI. RESULTS: Nutritional intervention and physical activity 
      before and during pregnancy are mandatory in women affected by GDM. Moreover, the 
      availability of insulin-sensitizers such as different forms of inositol has 
      dramatically changed the scenario, allowing the treatment of several metabolic 
      diseases, such as those related to glucose dysbalance. Although the optimal dose, 
      frequency, and form of MI administration need to be further investigated, diet 
      supplementation with MI appears to be an attractive alternative for the GDM 
      prevention as well as for the reduction of GDM-related complications. 
      CONCLUSIONS: More studies should be conducted to prove the most effective 
      nutritional intervention in GDM. Regarding the potential effectiveness of MI, 
      further evidence in multicenter, randomized controlled trials is needed to draw 
      firm conclusions.
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.net.
FAU - Reyes-Munoz, Enrique
AU  - Reyes-Munoz E
AD  - Department of Endocrinology, Instituto Nacional de Perinatologia Isidro Espinosa 
      de los Reyes, Mexico City, Mexico.
FAU - Guardo, Federica Di
AU  - Guardo FD
AD  - Department of General Surgery and Medical Surgical Specialties, University of 
      Catania, Catania, Italy.
FAU - Ciebiera, Michal
AU  - Ciebiera M
AD  - Second Department of Obstetrics and Gynecology, The Center of Postgraduate 
      Medical Education, Warsaw, Poland.
FAU - Kahramanoglu, Ilker
AU  - Kahramanoglu I
AD  - Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, 
      Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey.
FAU - Sathyapalan, Thozhukat
AU  - Sathyapalan T
AD  - Department of Diabetes and Endocrinology, University of Hull, Hull, United 
      Kingdom.
FAU - Lin, Li-Te
AU  - Lin LT
AD  - Department of Obstetrics and Gynecology, Kaohsiung Veterans General Hospital, 
      Kaohsiung, Taiwan.
FAU - Shah, Mohsin
AU  - Shah M
AD  - Department of Physiology, Institute of Basic Medical Sciences, Khyber Medical 
      University, Peshawar, Pakistan.
FAU - Karaman, Erbil
AU  - Karaman E
AD  - Department of Obstetrics and Gynecology, Yuzuncu Yil University Medical Faculty, 
      Van, Turkey.
FAU - Fan, Shangrong
AU  - Fan S
AD  - Department of Obstetrics and Gynecology, Peking University Shenzhen Hospital, 
      Shenzhen, China.
FAU - Zito, Gabriella
AU  - Zito G
AD  - Department of Obstetrics and Gynecology, Institute for Maternal and Child 
      Health-IRCCS "Burlo Garofolo", Trieste, Italy.
FAU - Noventa, Marco
AU  - Noventa M
AD  - Department of Woman and Child Health, University of Padua, Padua, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - Curr Pharm Des
JT  - Current pharmaceutical design
JID - 9602487
RN  - 4L6452S749 (Inositol)
SB  - IM
MH  - Diabetes, Gestational/*diet therapy/*prevention & control
MH  - Female
MH  - Humans
MH  - Inositol/*administration & dosage
MH  - Pregnancy
OTO - NOTNLM
OT  - Gestational diabetes mellitus
OT  - diet
OT  - management
OT  - metabolic diseases
OT  - myo-inositol
OT  - nutrition
OT  - prevention.
EDAT- 2019/07/25 06:00
MHDA- 2020/04/16 06:00
CRDT- 2019/07/24 06:00
PHST- 2019/07/01 00:00 [received]
PHST- 2019/07/20 00:00 [accepted]
PHST- 2019/07/25 06:00 [pubmed]
PHST- 2020/04/16 06:00 [medline]
PHST- 2019/07/24 06:00 [entrez]
AID - CPD-EPUB-99835 [pii]
AID - 10.2174/1381612825666190722155512 [doi]
PST - ppublish
SO  - Curr Pharm Des. 2019;25(22):2467-2473. doi: 10.2174/1381612825666190722155512.